Anti-sclerostin antibodies: Utility in treatment of osteoporosis

Medicine & Life Sciences

• romosozumab 100%
• blosozumab 77%
• Osteoporosis 63%
• Osteogenesis 62%
• Anti-Idiotypic Antibodies 60%
• Postmenopausal Osteoporosis 44%
• Monoclonal Antibodies 39%
• Bone Resorption 36%
• Bone Density 32%
• Bone and Bones 32%
• Osteocytes 22%
• Clinical Trials, Phase I 21%
• Bone Remodeling 18%
• Osteoblasts 17%
• Glycoproteins 15%
• Clinical Studies 12%
• Therapeutics 11%
• Safety 10%
• Mutation 10%
• Antibodies 9%
• Animals 8%
• Wounds and Injuries 8%
• Genes 7%

Chemical Compounds

• Glycoprotein 21%
• Disorder 20%
• Safety 20%
• Mutation 20%